BACKGROUND: Mycophenolic acid (MPA) is used off-label to treat many formsof glomerulonephritis. OBJECTIVE: To evaluate the pharmacokinetics of MPA and its glucuronide (MPAG) in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis patients with renal manifestations and to determine the effects of clinical (urinary proteinexcretion, serum albumin, creatinine clearance) and demographic (age, race, sex)variables on MPA and MPAG pharmacokinetics. METHODS: Twenty-three patients taking MPA at steady-statewere evaluated. Plasma and urine samples were collected over 24 hours. Analyses included noncompartmental pharmacokinetics and statistics including Mann-Whitney U test and univariate/multiple regression. RESULTS: MPA clearance (CUF 288 ± 154 mUmin) was approximately 2-fold higherthan previously reported from transplant patients and predicted by weight and race(ranked MPACIIF=-11.766 + 0.2035 [wt) + 4.9578 [race): R2 41 .8%:p =0.005).Creatinine clearance (CrCl) lessthan60 mUmin resulted in higherMPA exposure, total area underthe curve (AUC)o.l2' and AUC. l2 • as well as unbound AUCo.l2' The metabolic ratio (MPAG"ucfMPAA\lC) of 8.67 ± 5.57 was lower than thatpreviously reported in renal transplant recipients. CONCLUSIONS: Diminished kidneyfunction (eg, CrCl <1iO mUmin) demonstrated enhanced MPAand MPAG exposure in patients with ANCAvasculitis. However, unlike renal transplant recipients, patientswith ANCA vasculitis had enhanced CIIF and diminishedmetabolic ratio. suggesting the need to comprehensively evaluate the roleof disease-specific factors on MPA pharmacokinetics.
M ycophenolic acid (MPA) is used off-label for treatment of immunemediated disorders and is approved by the Food and Drug Administration (FDA) for prevention of transplant rejection."! Three studies evaluated the efficacy of MPA in small-vessel vasculitis." In one of these, we reported 3-fold improvements in disease activity (Birmingham Vasculitis Activity Score) in patients experiencing disease relapse compared with those defined as treatment resistant. While patients with kidney manifestations of vasculitis are similar to renal transplant recipients in that they can have alterations in glomerular filtration rate, they also often have altered serum albumin, urinary protein, and markers of inflammation.
Since interindividual variability in MPA pharmacokinetics has been documented in transplant recipients, therapeutic plasma monitoring has been suggested to improve immunosuppressive outcomes.P'" Area under the plasma concentration-time curve from 0 to 12 hours (AUC ool1 ) of 30-60 mg-h/L and trough plasma concentrations of 1-3.5 mg/L were suggested as targets for triple combination immunosuppressive therapy in kidney and heart transplant patients.u,l4 Target ranges for MPA in autoimmune kidney diseases, such as lupus nephritis and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, have not been established.
Authorinformation provided at the endof the text.
The primary purpose of this study was to evaluate the pharmacokinetics of total and unbound MPA and its metabolite, phenolic O-glucuronide (MPAG), in ANCA vasculitis. The secondary objectives were to determine the effects of clinical parameters (urinary protein to creatinine excretion ratio [UP:Cr], serum albumin, creatinine clearance [CrCI] ) and demographic variables (age, race, sex) on pharmacokinetics of the drug and its metabolite.
Methods

PATIENTS
Patientswith biopsy-confirmed ANCAvasculitis receiving MPAtherapy (as mycophenolate mofetil) and at steadystate were eligible. Concomitant therapies with other immunosuppressants werepermitted and recorded. Patients entered the institution's general clinical research unit for 24 hoursfor assessment of the pharmacokinetics of MPA at the doseand interval thatwasprescribed. Patients werefasting at study initiation and werethenfed a standard diet.CtCl (calculated by theCockcroft-Gault equation"), UP:Cr, serum albumin, and serum creatininewere obtained/recorded. The studywasapproved by the university's Institutional Review Board inaccordance withthe Declaration of Helsinki.
PHARMACOKINEnC STUDY
After baseline blood samples were obtained for measurement of a trough plasma concentration (Ctr), patients were instructedto take their morning dose of MPA.Plasma samples (7.5 mL) were obtainedat 0.5, 1,1.5,2,3,4, 6,8, 12, and 24 hours, immediately centrifuged for 10 minutesat 4 ·C, aliquoted, transferred to plasticscrew-top tubes,and storedat -80 ·C until assay. Urinewas collected at intervalsof 0-6, 6-12, and 12-24 hours into acidified (15 mL 6 N HCl) collection containers; volumes were recorded and 2-mL aliquots were storedat -80·C until assay.Plasmaand urinesamples were processed and assayed as described previously,":" Unboundplasma fractionwas determined as previously described." Plasma and urine standard curves for MPA were linear over the ranges of 0.2-200 and I-50 mg/L, respectively. Plasma and urine standard curves for MPAGwere linear over the ranges of 1-200 and 5-1500 mgIL,respectively. MPAGconcentrations were represented in terms of MPA equivalents by multiplying the MPAG concentration by 0.646 (molecular mass of MPA to MPAG) and are reported in milligrams per liter. The amountof MPAavailable from a doseof mycophenolate mofetil was estimated as 72% of the dose.
PHARMACOKINEnC ANALYSIS
Noncompartmental pharmacokinetic analysis of total and unbound MPA and total MPAGwas conductedusing WinNonlin v4.l (Pharsight, Mountain View,CA). Maximum concentration (C mu ) , time to C m •• (t ma . ) , Ctr at 12 hours, AUCO-I2, oral clearance (ClIF), renalclearance (Clr), and mean residence time (MRT) were recorded. Both concentration and AUC parameters were dose-normalized, and the clearance data were adjusted to a 70-kg patient based on a scaling method, using a power of 0.75. 18 We made the assumption thatbioavailability (F) wasequalto I, as reported previously," AUC U • 24 and AUC 6 • U were calcu-lated, and the latter was used to estimateapparententerohepatic recycling. 19 ,20 Amount of MPA and MPAG in urine over each collection was determinedby multiplying concentrationby volume. MPAand MPAG amounts in urine (Ae) were computedfor 0-12 hours by adding the Ae for the first2 intervals. Clr for the 0-to 12-hour time was calculatedby Aeo.u/AUCo.u' STATISTICS Descriptive analyses for pharmacokinetic and demographic variables and laboratories included means, standard deviations, and medians, as appropriate. Bivariate assessments of the key characteristics (serum albumin, UP:Cr, CtCI, age, weight, race, prednisone dose) versus each pharmacokinetic parameter of interest (MPA ClIF, AUC o.u, AUC6-12' ce., Clr, Cl unb, and AUCunbO-U ; as well as MPAG AUC o.u and Clr) were assessed by Spearman rank correlations. The effect of cyclosporine on MPA could not be directly assessed, because only 3 patients were receiving the drug. The correlations and resultant p values from the bivariate assessments were analyzed for possible inclusion into multiple regression models that predicted pharmacokinetic parameters.Correlations with a p value less than 0.15 were selected for incorporation into the multiple regression models. Variables were transformed to ensure that each followed a normaldistribution. Modelbuilding for analysis of determinants of the parameters identified aboveconsisted of multiple linearregression analysis withforward addition of variables as wellas backward elimination,noting influences on the coefficients of the primary predictors. The final modelwas selected based on significance of each variable on predicting the parameters in the model,as well as the overall R2 of the model.
Comparison between clinical groups based on CtCl «60 vs~60 mLImin) and UP:Cr (<500vs~OO) was analyzed by nonparametric Mann-Whitney U test. It was not possible to compare serumalbumin groups, as there wereno significant deviations from thelaboratory's reference range.
Results
Twenty-three patients with biopsy-confirmed ANCA small-vesselvasculitis completed the MPA/MPAG pharmacokinetics study. Patientdemographics included age 53 ± 14 years, 57% female, 78% white, and weight 87 ± 19 kg. Nonwhite racesconsisted of African American (n = 3), Asian (n =1),and other (n =1). All patientswere receiving the mycophenolate mofetil prodrug of MPA,with the exception of one patient (prescribed mycophenolate sodium), who was included in the analyses, as the pharmacokineticswere similar. The average MPA dailydose was 1489 ± 596 mg withdosingdivided twicedailyin all but one patient, who was dosed once daily. The distribution of doses 
MPAG PHARMACOKINETICS
The MPAG pharmacokinetic results are reported in Table I . A calculated AUC()'J1 ratio of MPAG to MPA resulted in a metabolic ratio of 8.67 ± 5.57.less than previously reported in renal transplant recipients."
The renal clearanceof MPAG was 33.7 ± 34.9 mUmin, representing40% of the crCl. The kidneys contributed to the elimination of 97% of the MPA dose, primarily through excretionof MPAG. The amount of MPAG in the urine over the 0-to 12-hour interval (513 ± 285 mg) was more than the amount in the 12-to 24-hour interval (378 ± 257 mg; p =0.017). The Clr was also greater in the 0-to 12-hour (33.7 ± 34.9 mUmin) versus 12-to 24-hour dosing interval (28.4 ± 36.9 mUmin; p = 0.0043). Figure 1 .The mean pharmacokinetic parameters for patients withANCA vasculitis are provided in Table  1 .The scaledClIFof 288 ± 154mUmin suggests that MPA is a moderate extraction ratiodrug whosemetabolism could be impacted by changes in unbound fraction. The mean percentageof unboundMPAwas 1.0± 0.6%, with all patients having unboundfractions of 2.4% or less,similarto the expectedunboundfraction.t'-" The MPAAUCo.11 was outside the 30to 6O-mg e hJL rangethat wasrecommended in kidney transplant patients within the first 6-monthperiodposttransplant,l1 with 22% (n =5) of patients above and 30% (n =7) belowthisrange.Examination of the AUC6-11 to the AUCo.J1 suggested that recycling accounted for 34 ± 10% of the AUC,whichis within the previously published range. 11 ,u
The Ctr at 12 hours exceededthe range of 1.0-3.5 mgIL that is recommended in transplant patients," with 22% (n =5) above this target. The t"..,. varied from 05 to 5 hours, severely limiting applicability of shortened plasma collec-: tions for AUC determination.
The MPACIr represented 2% of the ClIF, which is consistent with previous reports," As suggested previously, the clearance of MPA is primarily the result of systemic metabolism to MPAG.II The Clr of MPA was 5.77 ± 5.80 mUmin, which was 9% of the CrCl in our patients.
was 250 mg (n = 0,500 mg (n = 9),750 mg (n = 4), 1000 mg (n =8), and 1500 mg (n =I CrCl «60 mL/min vs~60 mL/min) were assessed ( Table  2 ). There was a considerable distribution of CrCl across the population (low 18.3 mL/min, high 182 mL/min). Since MPAGis eliminated via the renal route, reductions in renal elimination would be predicted to have more direct effects on MPAG, withsecondary effects on MPA due to potential enhanced MPA AUC6-12' reflective of enterohepatic recycling ( Table 2 ). The MPA Ctr valueswere 3-foldhigherin patients with reduced CrCl compared with those who had higher CrCl R2 41.8%; p = 0.005. The AUC6-12 showed the following relationship: Ln MPA A U412 = 3.706-0.0094(CtCl); R2 36.86%; P= 0.0021. In analysis ofMPA Clr,theAU412 was theonly significant contributing variable: ranked MPA Clr = 30.2674-6.2733(1n AUC6-12); R2 332%; p = 0.004.Regression assessment of the predictors for unbound MPA clearance indicated thatCrCl andage wereimportant: Ranked Cl unb = 16.055 + 0.0601(CrCl) -0.I994(age); R2 523%; p =0.0013. MPAG Clr analysis showed that race and prednisonedose contributed. Ln MPAG Clr = 2.6645 + 1.1799(race) -0.3041 (ranked prednisone dose); R2 88.0%; p = 0.014.
REGRESSION RESULTS
UNBOUND PHARMACOKINETICS
Our data showed that 1.0% and 13% of MPA and MPAG, respectively, wereunbound in the plasma. Since the unbound MPAG waslessthanthatreported previously," we performed studies with MPA and/or MPAG spiked heparinized plasma." The plasma that was spiked separately demonstrated similar unbound percentages to those found in our ANCApatient data; thecombination of drugand metaboliteresulted in an increase in unbound percentage of MPA and MPAG. This maybe suggestive of competitive binding to albumin, as has been reported previously,"
Since the normal percentage of unbound MPAis 2%, if one aims for a total MPA Ctr of 1.0-3.5 mgIL, thenan unbound target would be 0.02-0.07 mg/L," Likewise,if suggested total AUC goals are 30-60 mg-h/L, then unbound AUC goals would be 0.6-1.2 mg-h/L. Mean unbound Ctr levels were 0.04± 0.06mgIL (consistent at both the 12-and 24-h time points), with 5 patients exceeding the range and 13 patients below the range; thisresulted in only22% of all patients falling within the targeted kidney transplant range. With regard to unbound AUC, the mean exposurewas greater than the upper range of 1.2mg-h/L in only 1 patient,but was lessthanthetargeted range in 15patients.
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The Annals of Pharmacotherapy UP:Cr was selected as a clinical variable secondary to the high plasma protein binding characteristics of MPA and MPAG. To enable at least 5 observations per group, a cut-point of 500 mg/day was selected. None of the pharmacokinetic parameters was statistically significant between the high and low UP:Cr grouping. Only 4 patients had UP:Crgreaterthan 1.0g/day, preventing a comparison that may be more likely to be clinically relevant.
Discussion
While descriptions of the pharmacokinetics of MPAin patients who have undergonekidney transplant are abundant, there is a paucityof data on the pharmacokinetics in autoimmune diseases that affect the kidney. Our study was" conducted to comprehensively evaluate the pharmacokinetics of MPAand MPAG afterchronic therapy in patients withANCA-associated vasculitis. Additionally, we wanted to understand the relevance of clinical and demographic variables in predictingpharmacokinetic parameters. CrCl was positively predictive for MPA Cl unb and negatively predictive for MPAAUC6-12' Race was found to positively predictbothMPAClIFand MPAG Clr, whereby nonwhite patients had higher clearance values, suggestingan influence on both metabolism and Clr, Prednisonedosage was negatively associated with MPAG Clr, suggesting an influence on active renal secretion. Unfortunately, the influences of UP:Cr and serum albumin on pharmacokinetic variables were not able to be fully assessed secondary to limiteddistribution of UP:Cr and relatively conserved values of serumalbumin. A studyof MPA use in patients with lupus nephritis showedthat at a UP:Crof I g/dayor more, Ctr and AUC O • 12 were significantly reduced and ClIF was significantly increased," We previously reported higher MPA Cl unb and MPAG Clr levels in patients with lupus nephritis patients withserum albumin levels lessthan4 g/dL versus those withlevels greater than or equal to 4 g/dl.," CrCl significantly affected the pharmacokinetics of MPA and MPAG in ANCA-associated vasculitis. Al-thoughMPAitselfis not highly eliminated by the kidneys, exposure was markedlyenhanced in the low CrCl grouping, with dosing interval (AUC O • 12), enterohepatic recycling (AUC6-12)' and unbound (AUC O • 12unb) exposures being significantly greater. Since MPAG is primarilyeliminated by renal excretion,reductions in CrCl may predispose patients to higher concentrations of MPAG,which, through recycling,can increasesystemicexposureto MPA.These results suggest that patientswith diminished kidney function can reach targeted MPAexposure ranges with lower dosages,thus minimizing adverseevents.Lower unbound MPA (eg, AUC) would not be predicted to be increased through a purely restrictive clearance mechanism, and our patients were not hypoalbuminemic; hence, our data may suggest the influence of additional factors affecting plasma concentrations in patients withglomerular kidneydiseases. Assessmentof MPACtr values showed a consistent 2-to 3-fold higher value in patients with CrCl less than 60 mLimin compared with those with CrCl greater than 60 mUmin. When we performed a post hoc analysisof variance to evaluate the differences in pharmacokinetics based on CrCl groupings, we found that significant differences in Ctr, recycling AUC, unbound AVC, and unbound clearance were all demonstrated between the patients with chronic kidney disease stage 3/4 versus stage I group.
Only unbound clearance was found to also be significant betweenthe stage3/4 versus stage2 group.
The pharmacokinetics of MPA in patients with ANCA vasculitis are comparable with pharmacokinetics i~renal transplant patients, withthe exception ofCl/F, which'is about 2-foldgreaterin patients with vasculitis. Reasons for enhancedClIFcan include increased systemic metabolism secondary to upregulated glucuronidation, increased MPA unboundfraction, or enhanced renal excretion.Regarding enhanced glucuronidation, patients receiving concurrent steroids (enzyme inducers) had similar Cl/F estimates as patientswho were not receiving steroids (data not shown). We are currently evaluating the contributionof enhanced catalysis polymorphisms in the uridinediphosphate glucuronosyltransferases (UGTs) as factors altering MPAclearance.The metabolic ratio,a reflection of metabolite to parent AUC, was 8.67 ± 5.57 in our study,considerably less than the 25.6 ± 8.7 that was previously reported in kidney transplant recipients." The unbound fraction was relatively normal (-1 %) in our patients, as they had essentially normal serum albumin concentrations (3.6-5.2 g/dL). Enhancedrenalclearance Can resultfrom increased CrCI,loss of highly protein-bound drugs with urinary protein,or enhancedsecretory transport mechanisms. Our patients with ANCA vasculitis had a mean CrCl of 84 mL/min, with a range between 18 and 182 mUmin. Althoughrenal eliminationof MPA is limited, enhanced CrClcould resultin in-creasedclearance secondary to renalclearance of the polar metabolite MPAG. Enhanced renal clearance secondary to loss of the highly protein boundMPA withthe urinary protein could also account for an increase in ClIF. However, when we evaluated Clr between patients with UP:Cr less than500 mg/day andthose withUP:Cr greater thanor equal to 500 mg/day, the results were similar. The magnitude of differences in Clr between UP:Crgroups mayhavebeen underappreciated, basedon our selected cut-point. MPAG is a substrate for MRP2,an eftluxtransporter found on the luminal surface of the proximal tubule. Theoretically, singlenucleotide polymorphisms (SNPs) in this transport genecan resultin enhanced activity and couldincrease the renal excretion ofMPAG,limiting theeffect of recycling.
Renal transplant recipients,similar to our ANCA vasculitis patients, generally havereductions in crCl. A previous study used a multivariateanalysis and demonstrated that 24% of the MPAClIFcould be explained by proteinuria(yes/no), glomerular filtration rate, and diabetes mellitus." Unfortunately,the range of proteinuria required to designate a yes versusno categorization was not reported. Our regression data showed that CrCl was predictivefor both Cl unb and AUC,.\2' Previous data on lupus nephritis from our laboratory showed that 51% of MPAClIFcould be explained by CrCl and serum albumin,2 readily measured clinical laboratory measures}' The contribution of race to MPA ClIFin our vasculitis patients requires assessment of genotype as a confounding variable,as genomic effects havebeen shown to influence the pharmacokinetics of MPA.19.20.2' CrCl would generally be predicted to contribute little to MPA ClIF, secondary to the low percentage of MPA (1-3%) that is normallyexcreted by the kidneys.' Hence,nonrenal clearance, through metabolism of MPA to MPAG, would comprise the largest bulk of the CIIF for MPA.Our regression analyses demonstrated that AUC,.u was the only significant predictor of MPA Clr,demonstrating an influence of MPA plasma concentration on Clr.The regression models are important, as they provide insights into the mechanisms that may underlie the alterations in pharmacokinetics seen in disease states such as ANCA-associated vasculitis. This is particularly important, since there is a paucity of published research on medication offlabel disease groups,whereby therecan be extensive varia-.tions in medication handling versus in the diseases for whichthe drugswereFDA approved.
Unlike our ANCA vasculitis patients,our previousreport on MPA pharmacokinetics in patients with lupus nephritisshowed higher UP:Cr and lower serum albumin and CrCl}' The key differences in pharmacokinetics of MPA and MPAG between thesestudies included enhanced MPA MRT, MPA Clr,metabolic ratio (MPAGAUdMPAAUC>, unbound MPAG %, and MPA CIIF unb ; reduced MPA AUCo.\2' MPA AUC6-\2' MPAG Clr,MPA Ctr unb ' and MPA Mycophenolic Acid Pharmacokinetics in Vasculitis AUC unb ; and normal unbound MPA % in the ANCA vasculitis versus lupusnephritis population. Thesedata generally demonstrate lesser MPA exposure in patients with ANCA-associated vasculitis as opposed to those with lupus nephritis. While lower MPA dosages in the ANCA vasculitis populations couldreflectreducedexposure,our data were dose-normalized to eliminate the dose effect. The effects of SNPs in UGT enzymes requires assessment in theseautoimmune diseases, especially sinceenvironmental exposure is thoughtto playa role in their etiology and since the UGTenzymes playa rolein thebody'snatural defense against environmental toxins. Additionally, theroleof inflammation in MPA pharmacokinetics in autoimmune diseasesrequires evaluation as a potential disease component thatmaymodify drug metabolism andtransport.
While we reportthe contribution of CrCl to MPA clearance and exposure in a model of ANCA vasculitis, there are some limitations to our research. As notedpreviously, our patients had preserved serum albumin concentrations, preventing full assessment of the contribution of reductions in serumalbumin on clearance. Similarly, sinceonly 4 patients in our dataset had UP:Cr of approximately I g/day and none had nephrotic-range proteinuria (UP:Cr >3.5 g/day), the full contribution of UP:Cr to clearance may actually be underrecognized. Future analyses of our data include assessment of the contribution of genotype for drug-metabolizing enzymes and transporters on clearance and outcomes, as wellas the analysis of the contribution of Ctr and AUC to patientoutcomes. Our studies on autoimmune-related kidney diseases are important, as they provide a framework to understand the contributions of disease-related and -unrelated factors to MPA exposure. A goalof our future work is to betterdefine appropriate MPA concentration or exposure targets for patients withANCAassociated vasculitis.
Approaches to comprehensively evaluatethe influence of clinicaland demographic factors on MPApharmacokinetics are neededto begin to identifyvariables that could be used to individualizetreatment strategies for patients with ANCA-associated vasculitis.
OBJETIVOS: Los objetivosde este estudiofueronevaluarlas propiedades farmacocinedcas de MPAy su metabolito glucuronide (MPAG) en pacientes con vasculitis asociadaa anticuerpos citoplasrnicos antineutr6fi1os (ANCA)y manifestaeiones renales.Tambien se determin6el efectode las variables clfnicas(exereci6n de protefna urinaria,albuminaserica y depuraci6n de creatinina) y demograflcas (edad,raza y genero)en la farmacocinetica de MPAy MPAG. 
